1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. UK CONTINUOUS GLUCOSE MONITORING MARKET BY GENDER
5.1. Introduction
5.2. Male
5.3. Female
6. UK CONTINUOUS GLUCOSE MONITORING MARKET BY AGE
6.1. Introduction
6.2. Adults (>14 Years)
6.3. Children (<=14 Years)
7. UK CONTINUOUS GLUCOSE MONITORING MARKET BY TYPE
7.1. Introduction
7.2. Real-time CGM
7.3. Intermittent CGM
8. UK CONTINUOUS GLUCOSE MONITORING MARKET BY APPLICATION
8.1. Introduction
8.2. Diabetes Patients
8.3. Critical Care Patients
9. UK CONTINUOUS GLUCOSE MONITORING MARKET BY END-USERS
9.1. Introduction
9.2. Hospitals and Clinics
9.3. Homecare
9.4. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Abbott Laboratories
11.2. Dexcom, Inc.
11.3. Medtronic PLC
11.4. Senseonics Holdings, Inc.
11.5. Ascensia Diabetes Care Holdings AG
11.6. Nemaura Medical Inc.
11.7. GlucoRx Limited
11.8. A. Menarini Diagnostics S.r.l.
11.9. Ypsomed Holding AG
11.10. Roche Diagnostics
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key benefits for the stakeholders
12.5. Research Methodology
12.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES